A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating Neoadjuvant Therapy Targeting the Adenosine Immunosuppressive Pathway in Combination With Immune Checkpoint Blockade and Radiation Therapy in Patients With Advanced PANCreatic Ductal Adenocarcinoma Who Are Candidates for Surgical Resection

The purpose of this study is to combine standard radiation therapy with drugs that encourages the body's immune system against cancer cells and simultaneously adding drugs which also target the pathway that the tumor uses to evade the immune system (CD73 and A2a/b). The study hopes that these drugs will work in concert with radiation therapy to kill cancer cells.
The specific goal of this study is to ensure that treatment with zimberelimab and stereotactic body radiation therapy (SBRT) alone or in combination with quemliclustat (a drug which blocks CD73), with or without etrumadenant (a drug which blocks the A2a/b) given before surgery is safe and if it can further increase the immune response against the tumor.

开始日期2024-05-10

申办/合作机构

Arcus Biosciences, Inc.

NCT04892875

/ Withdrawn临床1期IIT

A Phase Ib Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN)

The purpose of this study is to test the safety and tolerability of chemotherapy and radiation in combination with the investigational study drugs zimberelimab (AB122) and etrumadenant (AB928) in subjects with a locally advances head or neck cancer. The study will also ask how the study drugs change the following:
* The microbiome that lives in the mouth and on the skin
* Immune cells as they respond to a skin wound
* Scarring (fibrosis) caused by radiation
After completing a screening phase, subjects will be assigned to one of three cohorts:
* Cohort 1: Subjects who will receive cisplatin, radiation and zimberelimab followed by zimberelimab only.
* Cohort 2: Subjects who will receive cisplatin, radiation, zimberelimab and etrumadenant followed by zimberelimab and etrumadent.
* Cohort 3: Subjects who will receive cisplatin and radiation followed by an observation period.
All three cohorts will be followed for a 24 months following the conclusion of the chemoradiation.

开始日期2023-12-31

申办/合作机构

The Vanderbilt-Ingram Cancer Center

[+1]

NCT05915442

/ Recruiting临床2期IIT

Phase II Single Arm Study Testing SBRT, Adenosine Signaling Modulation (AB680, AB928), and Immune Checkpoint Inhibition (AB122) for Men With Hormone Sensitive Oligometastatic Prostate Cancer

This study will evaluate the safety and effectiveness of a combination of study drugs including zimberelimab, etrumadenant, and quemliclustat in combination with metastasis-directed irradiation in men with hormone sensitive oligometastatic prostate cancer.
The study aims to test the hypothesis that targeted inhibition of the adenosine signaling axis (quemliclustat (CD73 antagonist) + etrumadenant (A2AR/A2BR antagonist)) and immune checkpoint inhibition (zimberelimab, α-PD-1) in combination with metastasis-directed stereotactic body radiation therapy (SBRT) will improve local control, progression-free survival (PFS), and hormone therapy-free survival and mitigate immunosuppressive changes to the tumor microenvironment (TME), compared to SBRT alone.

开始日期2023-07-01

申办/合作机构

Columbia University

[+1]

100 项与 Etrumadenant 相关的临床结果

登录后查看更多信息

100 项与 Etrumadenant 相关的转化医学

登录后查看更多信息

100 项与 Etrumadenant 相关的专利（医药）

登录后查看更多信息

项与 Etrumadenant 相关的文献（医药）

2026-01-01·EBioMedicine

Reversing adenosine-mediated immunosuppression in triple-negative breast cancer by synergistic chemo-immunotherapy via stimuli-responsive nanomedicines

Article

作者: Hu, Na ; Li, Xue ; Jing, Jing ; Cai, Hao ; Lui, Su ; Gong, Qiyong ; Cheng, Xinying ; Li, Siying ; Li, Yunkun ; Zhang, Yuxin ; Luo, Kui

BACKGROUND:

Chemotherapy remains the first-line treatment for triple-negative breast cancer (TNBC). Anthracycline chemotherapeutics, such as epirubicin (EPI), not only kill tumor cells but also induce immunogenic cell death (ICD). However, accumulated extracellular adenosine triphosphate (eATP) during ICD is converted to adenosine, triggering immunosuppression via adenosine receptor signalling. To address this issue, co-administration of EPI with adenosine receptor antagonists could remodel the immunosuppressive tumor microenvironment and potentiate antitumor immunity.

METHODS:

The effect of the expression level of adenosine receptors on the immune microenvironment of TNBC was assessed by integrating bioinformatic analysis of public databases with immunofluorescence staining of TNBC clinical samples. Four polymeric prodrugs of EPI were synthesised, and their delivery performances were assessed. A nanomedicine with pH/cathepsin B (CTSB)-responsiveness for co-delivery of EPI and AB928 (an adenosine receptor antagonist) was constructed. The cellular experiments and 4T1 tumor-bearing mice model were employed to evaluate antitumor efficacy.

FINDINGS:

Bioinformatic analyses and immunofluorescence staining of TNBC clinical samples supported the rationale for combining ICD-inducing chemotherapeutic agents with adenosine receptor antagonists. The polymeric prodrug of EPI with an optimal delivery efficiency was selected to encapsulate AB928. The constructed nanomedicine for EPI/AB928 co-delivery enhanced antitumor immune responses by effectively inhibiting adenosine-A2A receptor/A2B receptor (A2AR/A2BR) signalling pathways and reversing adenosine-mediated immunosuppression.

INTERPRETATION:

Co-delivery of an ICD inducer (EPI) and an adenosine receptor antagonist (AB928) is realised in a stimuli-responsive nanomedicine to address immunosuppression induced by adenosine, thereby enhancing ICD effects and synergistically reprogramming the immunosuppressive tumor microenvironment.

FUNDING:

See Acknowledgements.

2025-08-01·BIOORGANIC CHEMISTRY

Design, synthesis, and biological evaluation of A2A adenosine receptor antagonists containing pyrrolo[2,3-d]pyrimidin-2-amine skeleton

Article

作者: Xie, Zeping ; Wang, Yunqing ; Liu, Ming ; Liu, Jiaqi ; Fu, Xinzhen ; Xu, Maolei ; Zhang, Shumin ; Kou, Lijuan ; Li, Zhi ; Zhao, Wanzhu ; Guo, Lin

A series of novel A_2A adenosine receptor (AR) antagonists containing a pyrrolo[2,3-d]pyrimidin-2-amine skeleton were developed through a bioisosterism strategy based on human A_2A AR structures. The synthesis of all targeted compounds was accomplished, and their inhibitory effectiveness against the A_2A AR was assessed using cAMP assays. Notably, compounds 12a and 18e demonstrated superior inhibitory effects compared to the control compounds AB928 and ZM241385. Competitive radioligand binding experiments confirmed their high binding affinities to the A_2A AR. Molecular docking studies revealed that the pyrrolo[2,3-d]pyrimidin-2-amine core moiety forms two π-π interactions with the aromatic residue Phe168, alongside forming hydrogen bonds with residues Glu169 and Asn253. This information elucidates the rationality of molecular design. Moreover, both compounds 12a and 18e exhibited negligible toxicity towards normal cell lines. Compound 12a also demonstrated favorable stabilities in liver microsomes and acceptable pharmacokinetic profiles in vivo. These findings underscore the promise of compound 12a as a leading candidate for further research and development, highlighting its potential therapeutic applications.

2025-06-01·EUROPEAN JOURNAL OF PHARMACOLOGY

A novel adenosine 2A receptor antagonist HZ-086 enhances the efficiency of immunotherapy and alleviates the acquired resistance to PD-L1 by restoration of T cell functions

Article

作者: Ouyang, Shumin ; Peng, Keren ; Wang, Pengyan ; Mo, Jianshan ; Lu, Jinjian ; Zhang, Qiyi ; Liu, Guopin ; Wang, Yandong ; Gu, Chenxi ; Zhang, Xiaolei ; Ding, Wen ; Hu, Wenhao ; Zhu, Kai

Immunotherapy faces significant challenges due to low clinical response rates and immune escape mechanisms, which ultimately lead to drug resistance. Previous studies suggest that adenosine-2A receptor (A_2AR) signaling plays a critical role in immunosuppression and immune escape. However, no potent and selective A_2AR inhibitors are currently available for clinical use to address immunotherapy resistance in tumors. In this study, we identified a novel small molecule compound, HZ-086, as a potent and selective inhibitor of A_2AR. HZ-086 restored the activation of T-cell signaling which is suppressed by adenosine analogs in vitro. Additionally, HZ-086 enhanced T-cell-mediated cytotoxicity, increased the secretion of cytokines for antitumor and subsequently inhibited growth of tumor cells in vitro and in vivo. Furthermore, HZ-086 inhibited tumor growth, enhances anti-tumor capacity, and reversed PD-L1 resistance in vivo. When combined with FD-L1, a PD-L1 small molecule inhibitor discovered by our lab, HZ-086 achieved over 80 % tumor growth inhibition (TGI) and restored immune response in anti-PD-L1 monoclonal antibody-resistant tumors. This combination treatment also promoted the infiltration and activation of CD8⁺ T lymphocytes within the tumor microenvironment. Our findings demonstrate that adenosine-A_2AR signaling mediates resistance to immunotherapy and discover a novel potent and selective A_2AR inhibitor with high efficacy in enhancing antitumor immune responses and reversing PD-L1 resistance. The combination of A_2AR inhibitor and PD-L1 inhibitor represents a promising therapeutic strategy for antitumor therapy.

104

项与 Etrumadenant 相关的新闻（医药）

2026-01-13

·LONGPORT

Arcus Biosciences (NYSE:RCUS) 股价跳空上涨 - 事情的经过

Arcus Biosciences（纽约证券交易所代码：RCUS）股价在开盘前从 21.30 美元跳涨至 22.19 美元，最终收于 22.43 美元，成交量为 1,292,918 股。分析师们设定了不同的目标价，Truist Financial 为 30.00 美元，Wells Fargo 为 29.00 美元。该公司报告的季度收入为 2600 万美元，超出预期，但每股收益为负（1.27 美元）。公司高管进行了股票出售，首席执行官 Terry J. Rosen 出售了价值 633,360 美元的股票。机构投资者最近也增加了对该公司的持股Arcus Biosciences, Inc. (NYSE:RCUS - 获取免费报告) 的股票在周二交易前出现了跳空上涨。该股票之前收盘价为 21.30 美元，但开盘价为 22.19 美元。Arcus Biosciences 的股票最后交易价格为 22.4330 美元，成交量为 1,292,918 股。获取 Arcus Biosciences 的提醒：分析师设定新的价格目标从滞后者到领头羊：小型股正在崛起 RCUS 最近成为多份研究报告的主题。Truist Financial 在 12 月 12 日的研究报告中将 Arcus Biosciences 的股票目标价设定为 30.00 美元。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Arcus Biosciences 的 “卖出（d-）” 评级。Wells Fargo & Company 在 10 月 20 日的研究报告中将 Arcus Biosciences 的目标价从 25.00 美元上调至 29.00 美元，并给予该公司 “增持” 评级。摩根士丹利在 1 月 8 日的报告中重申了 “持平” 评级，并将 Arcus Biosciences 的目标价设定为 20.00 美元（从 23.00 美元下调）。最后，高盛集团在周一将 Arcus Biosciences 的评级从 “中性” 上调至 “买入”，并将该公司的目标价从 16.00 美元上调至 28.00 美元。八位股票研究分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Arcus Biosciences 目前的共识评级为 “适度买入”，平均目标价为 30.00 美元。获取我们对 RCUS 的最新股票分析 Arcus Biosciences 股票上涨 4.8% MarketBeat 周回顾 – 7/10 - 7/14 该公司的市值为 24.1 亿美元，市盈率为-6.49，贝塔值为 0.77。公司的债务与股本比率为 0.22，流动比率为 3.65，速动比率为 3.65。该业务的 50 日移动平均价格为 22.62 美元，200 日移动平均价格为 15.72 美元。 Arcus Biosciences (NYSE:RCUS - 获取免费报告) 最近于 10 月 28 日发布了其财报。该公司报告本季度每股收益为 (-1.27) 美元，超出分析师共识预期的 (-1.33) 美元 0.06 美元。Arcus Biosciences 的股本回报率为-68.17%，净利润率为-136.40%。该公司本季度的收入为 2600 万美元，而分析师预期为 1989 万美元。在去年同期，该公司每股收益为 (-1.00) 美元。Arcus Biosciences 本季度的收入同比下降了 45.8%。平均而言，股票分析师预计 Arcus Biosciences, Inc.在本年度将发布每股收益为-3.15 美元。内部买卖吉利德通过在 AlloVir 和 Arcus 的股份扩大生物技术足迹在相关消息中，首席执行官 Terry J. Rosen 于 12 月 16 日星期二出售了 28,947 股公司的股票。股票以平均价格 21.88 美元出售，总交易额为 633,360.36 美元。交易完成后，首席执行官直接持有公司 2,220,553 股，价值 48,585,699.64 美元。此次交易使其持股比例减少了 1.29%。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，首席运营官 Jennifer Jarrett 于 12 月 16 日星期二出售了 11,225 股公司的股票。股票以平均价格 21.88 美元出售，总交易额为 245,603.00 美元。交易完成后，首席运营官直接持有公司 203,007 股，价值约 4,441,793.16 美元。此次交易使其持股比例减少了 5.24%。该销售的 SEC 文件提供了更多信息。在过去 90 天内，内部人士共出售了 422,060 股公司股票，价值 9,286,202 美元。内部人士持有公司股票的比例为 9.60%。机构资金流入和流出机构投资者最近买卖了该股票的股份。GAMMA Investing LLC 在第三季度将其在 Arcus Biosciences 的股份增加了 59.1%。GAMMA Investing LLC 目前拥有 2,748 股公司股票，价值 37,000 美元，此前在上个季度又购买了 1,021 股。SBI Securities Co. Ltd.在第三季度将其在 Arcus Biosciences 的股份增加了 13,547.6%。SBI Securities Co. Ltd.目前拥有 2,866 股公司股票，价值 39,000 美元，此前在上个季度又收购了 2,845 股。Abich Financial Wealth Management LLC 在第三季度购买了 Arcus Biosciences 的新股份，价值 69,000 美元。CWM LLC 在第二季度将其在 Arcus Biosciences 的股份增加了 233.6%。CWM LLC 目前拥有 5,441 股公司股票，价值 44,000 美元，此前在上个季度又收购了 3,810 股。最后，Ameritas Investment Partners Inc.在第二季度将其在 Arcus Biosciences 的股份增加了 34.3%。Ameritas Investment Partners Inc.目前拥有 7,038 股公司股票，价值 57,000 美元，此前在上个季度又收购了 1,796 股。92.89% 的股票目前由对冲基金和其他机构投资者持有。 Arcus Biosciences 公司简介 (获取免费报告) Arcus Biosciences 是一家临床阶段的生物制药公司，专注于新型癌症免疫疗法的发现、开发和商业化。该公司的研究平台集中在通过小分子和抗体候选药物调节肿瘤微环境和免疫检查点。Arcus 旨在通过靶向腺苷轴和免疫细胞上的抑制受体等途径增强抗肿瘤免疫反应。该公司的主要临床项目包括 etrumadenant，一种口服给药的 A2A 腺苷受体拮抗剂，正在与抗 PD-1 疗法联合评估，以及 domvanalimab，一种抗 TIGIT 单克隆抗体。进一步阅读我们更看好的五只股票，胜过 Arcus Biosciences 埃隆将 SpaceX 上市！$100 的首次公开募股机会！家族信托如何帮助保护您的财富一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地被激活股票代码揭晓：获得 “下一个埃隆·马斯克” 公司的首次公开募股机会崩盘已经开始（大多数人还未察觉）此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。您现在应该投资 $1,000 在 Arcus Biosciences 吗？在您考虑 Arcus Biosciences 之前，您需要听听这个。 MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Arcus Biosciences 并不在名单上。虽然 Arcus Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。在这里查看这五只股票 Arcus Biosciences, Inc. (NYSE:RCUS - 获取免费报告) 的股票在周二交易前出现了跳空上涨。该股票之前收盘价为 21.30 美元，但开盘价为 22.19 美元。Arcus Biosciences 的股票最后交易价格为 22.4330 美元，成交量为 1,292,918 股。获取 Arcus Biosciences 的提醒：分析师设定新的价格目标从滞后者到领头羊：小型股正在崛起 RCUS 最近成为多份研究报告的主题。Truist Financial 在 12 月 12 日的研究报告中将 Arcus Biosciences 的股票目标价设定为 30.00 美元。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Arcus Biosciences 的 “卖出（d-）” 评级。Wells Fargo & Company 在 10 月 20 日的研究报告中将 Arcus Biosciences 的目标价从 25.00 美元上调至 29.00 美元，并给予该公司 “增持” 评级。摩根士丹利在 1 月 8 日的报告中重申了 “持平” 评级，并将 Arcus Biosciences 的目标价设定为 20.00 美元（从 23.00 美元下调）。最后，高盛集团在周一将 Arcus Biosciences 的评级从 “中性” 上调至 “买入”，并将该公司的目标价从 16.00 美元上调至 28.00 美元。八位股票研究分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Arcus Biosciences 目前的共识评级为 “适度买入”，平均目标价为 30.00 美元。获取我们对 RCUS 的最新股票分析 Arcus Biosciences 股票上涨 4.8% MarketBeat 周回顾 – 7/10 - 7/14 该公司的市值为 24.1 亿美元，市盈率为-6.49，贝塔值为 0.77。公司的债务与股本比率为 0.22，流动比率为 3.65，速动比率为 3.65。该业务的 50 日移动平均价格为 22.62 美元，200 日移动平均价格为 15.72 美元。 Arcus Biosciences (NYSE:RCUS - 获取免费报告) 最近于 10 月 28 日发布了其财报。该公司报告本季度每股收益为 (-1.27) 美元，超出分析师共识预期的 (-1.33) 美元 0.06 美元。Arcus Biosciences 的股本回报率为-68.17%，净利润率为-136.40%。该公司本季度的收入为 2600 万美元，而分析师预期为 1989 万美元。在去年同期，该公司每股收益为 (-1.00) 美元。Arcus Biosciences 本季度的收入同比下降了 45.8%。平均而言，股票分析师预计 Arcus Biosciences, Inc.在本年度将发布每股收益为-3.15 美元。内部买卖吉利德通过在 AlloVir 和 Arcus 的股份扩大生物技术足迹在相关消息中，首席执行官 Terry J. Rosen 于 12 月 16 日星期二出售了 28,947 股公司的股票。股票以平均价格 21.88 美元出售，总交易额为 633,360.36 美元。交易完成后，首席执行官直接持有公司 2,220,553 股，价值 48,585,699.64 美元。此次交易使其持股比例减少了 1.29%。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，首席运营官 Jennifer Jarrett 于 12 月 16 日星期二出售了 11,225 股公司的股票。股票以平均价格 21.88 美元出售，总交易额为 245,603.00 美元。交易完成后，首席运营官直接持有公司 203,007 股，价值约 4,441,793.16 美元。此次交易使其持股比例减少了 5.24%。该销售的 SEC 文件提供了更多信息。在过去 90 天内，内部人士共出售了 422,060 股公司股票，价值 9,286,202 美元。内部人士持有公司股票的比例为 9.60%。机构资金流入和流出机构投资者最近买卖了该股票的股份。GAMMA Investing LLC 在第三季度将其在 Arcus Biosciences 的股份增加了 59.1%。GAMMA Investing LLC 目前拥有 2,748 股公司股票，价值 37,000 美元，此前在上个季度又购买了 1,021 股。SBI Securities Co. Ltd.在第三季度将其在 Arcus Biosciences 的股份增加了 13,547.6%。SBI Securities Co. Ltd.目前拥有 2,866 股公司股票，价值 39,000 美元，此前在上个季度又收购了 2,845 股。Abich Financial Wealth Management LLC 在第三季度购买了 Arcus Biosciences 的新股份，价值 69,000 美元。CWM LLC 在第二季度将其在 Arcus Biosciences 的股份增加了 233.6%。CWM LLC 目前拥有 5,441 股公司股票，价值 44,000 美元，此前在上个季度又收购了 3,810 股。最后，Ameritas Investment Partners Inc.在第二季度将其在 Arcus Biosciences 的股份增加了 34.3%。Ameritas Investment Partners Inc.目前拥有 7,038 股公司股票，价值 57,000 美元，此前在上个季度又收购了 1,796 股。92.89% 的股票目前由对冲基金和其他机构投资者持有。 Arcus Biosciences 公司简介 (获取免费报告) Arcus Biosciences 是一家临床阶段的生物制药公司，专注于新型癌症免疫疗法的发现、开发和商业化。该公司的研究平台集中在通过小分子和抗体候选药物调节肿瘤微环境和免疫检查点。Arcus 旨在通过靶向腺苷轴和免疫细胞上的抑制受体等途径增强抗肿瘤免疫反应。该公司的主要临床项目包括 etrumadenant，一种口服给药的 A2A 腺苷受体拮抗剂，正在与抗 PD-1 疗法联合评估，以及 domvanalimab，一种抗 TIGIT 单克隆抗体。进一步阅读我们更看好的五只股票，胜过 Arcus Biosciences 埃隆将 SpaceX 上市！$100 的首次公开募股机会！家族信托如何帮助保护您的财富一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地被激活股票代码揭晓：获得 “下一个埃隆·马斯克” 公司的首次公开募股机会崩盘已经开始（大多数人还未察觉）此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。您现在应该投资 $1,000 在 Arcus Biosciences 吗？在您考虑 Arcus Biosciences 之前，您需要听听这个。 MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Arcus Biosciences 并不在名单上。虽然 Arcus Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。在这里查看这五只股票

财报并购IPO微生物疗法

2025-12-03

·西学中论坛

腺苷及其衍生物的临床应用综述：从传统心血管领域到新兴治疗前景

摘要腺苷及其衍生物作为一类具有广泛生理活性的内源性物质和药物，在心血管疾病、病毒感染、血液系统疾病乃至肿瘤免疫治疗等领域展现出重要的临床应用价值。本文系统综述了腺苷及其相关药物的药理机制、临床应用适应症、联合用药策略及最新研究进展。基于2024年发布的《腺苷注射液在心血管疾病诊疗中的临床应用中国专家共识》等权威指南，重点阐述了腺苷在心血管疾病诊断与治疗中的核心地位，特别是在冠心病无创诊断、阵发性室上性心动过速终止以及冠状动脉微循环保护等方面的规范化应用。同时，本文也探讨了单磷酸阿糖腺苷、腺苷钴胺等衍生物在不同疾病领域的治疗潜力，并展望了腺苷信号通路在肿瘤免疫治疗中的新兴应用前景。通过整合临床文献、专家共识及实践经验，本文旨在为临床医生提供系统、循证的腺苷类药物使用指导，促进精准化、个体化治疗策略的实施。1 引言腺苷（Adenosine）是一种在人体所有细胞中普遍存在的内源性嘌呤核苷，通过激活细胞表面的四种G蛋白偶联受体（A1、A2A、A2B和A3），参与调节心血管、神经、免疫等多系统的生理功能与病理过程。在基础生理状态下，腺苷维持低水平释放；当组织面临缺血、缺氧、炎症或损伤时，其浓度会迅速反应性升高，通过调节能量代谢、减轻组织损伤和促进修复等机制发挥保护作用。这种独特的生理特性使其成为连接细胞代谢状态与功能调节的关键信使分子。近年来，随着对腺苷信号通路研究的深入，其临床应用已从传统的心血管领域迅速扩展到抗病毒感染、神经修复、肿瘤免疫等多个前沿方向。特别是2024年《腺苷注射液在心血管疾病诊疗中的临床应用中国专家共识》的发布，标志着我国对腺苷临床应用的认识达到了新的高度，为其规范化、精准化使用提供了权威指导。本综述旨在系统梳理腺苷及其衍生物的临床应用全貌，整合最新循证证据与专家共识，为临床实践提供全面参考。2 腺苷的药理基础与药物分类2.1 核心药理机制腺苷通过与靶细胞膜上四种亚型的腺苷受体结合，激活不同的细胞内信号通路，产生多样化的生物效应：· A1受体激活：主要导致心脏负性变时、变传导和变力作用，抑制神经元兴奋性和脂肪分解。· A2A受体激活：引起冠状动脉和外周血管扩张，抑制血小板聚集和炎症反应。· A2B受体激活：参与血管生成、炎症介质释放和细胞因子产生调节。· A3受体激活：调控细胞凋亡和炎症反应，具有心脏保护作用。腺苷在体内的代谢极其迅速，血浆半衰期不足10秒，主要通过细胞摄取（红细胞和内皮细胞）及随后的磷酸化或脱氨作用清除，这一特点使其作用短暂可控，尤其适合诊断性应用。值得注意的是，外源性腺苷的代谢不受肝肾功能影响，为肝肾功能不全患者的使用提供了便利。2.2 主要药物分类及特点（1）腺苷注射液· 核心适应症：主要用于终止阵发性室上性心动过速（PSVT），特别是在房室结参与折返的情况下可作为首选药物。同时也广泛用于核素心肌灌注显像的药物负荷试验。· 给药特点：需快速静脉注射（1-2秒内完成），作用起效快（10-20秒），持续时间短。（2）单磷酸阿糖腺苷· 药物性质：一种抗脱氧核糖核酸（DNA）病毒药，为腺苷的衍生物。· 核心适应症：主要用于治疗疱疹病毒感染，如小儿疱疹性口腔炎。近期研究也支持其用于治疗小儿毛细支气管炎。（3）腺苷钴胺· 药物性质：为氰钴型维生素B12的同类物，是人体内维生素B12的活性辅酶形式之一。· 核心适应症：适用于巨幼红细胞性贫血、多发性神经炎、神经麻痹等疾病。（4）新型腺苷受体调节剂包括瑞加诺生（选择性A2A受体激动剂）以及处于临床试验阶段的A2A/A2B受体拮抗剂、CD73抑制剂等，主要用于心血管负荷诊断和肿瘤免疫治疗。3 心血管疾病诊疗中的核心应用3.1 冠心病无创诊断：药物负荷试验的关键角色腺苷在心血管领域最重要的应用之一是作为药物负荷试验的激发剂，用于评估冠状动脉血流储备和诊断心肌缺血。1. 负荷超声心动图与心肌灌注显像腺苷通过激动血管内皮细胞A2受体，引起冠状动脉（尤其是微小动脉）扩张，使正常冠状动脉的血流量增加3-5倍，而狭窄动脉的血流增加有限，从而暴露出心肌血流分布的不均匀性。与传统运动负荷试验相比，药物负荷试验适用于无法充分运动或心电图存在干扰的患者，拓宽了冠心病的诊断范围。2. 新型腺苷类负荷药物的进展传统腺苷虽有效，但可能引起支气管痉挛、房室传导阻滞等不良反应。近年来，选择性A2A受体激动剂瑞加诺生的应用是一大进展。与传统腺苷相比，瑞加诺生能选择性扩张冠状动脉，对支气管平滑肌影响小，不良反应更少，且操作简便（单次静脉注射即可），患者耐受性更好。研究表明，瑞加诺生在提高对心肌缺血及冠状动脉微血管疾病的诊断率方面具有优势。3.2 阵发性室上性心动过速的终止治疗腺苷是终止房室结折返性心动过速（AVNRT）和房室折返性心动过速（AVRT）的一线药物。其作用机制是通过激活心脏A1受体，短暂抑制房室结传导，从而打断折返环路。临床用药方案：成人初始剂量为3mg，在1-2秒内快速静脉注射，随后用生理盐水快速冲洗。若1-2分钟后未转复，可给予第二剂6mg，必要时再给予第三剂12mg。值得注意的是，腺苷对心房扑动、心房颤动或室性心动过速通常无转复作用，但其引起的短暂房室传导阻滞有助于显露心房活动，具有鉴别诊断价值。3.3 冠状动脉微循环保护与心肌再灌注损伤的防治冠状动脉微循环功能障碍（CMVD）是心血管预后的独立预测因子，但直接观察微血管结构在临床上仍具挑战。腺苷在这一领域显示出独特的应用价值。1. 微循环功能评估临床上常将腺苷扩张微血管的作用与心肌声学造影、核素心肌灌注显像、CT心肌灌注等无创检查结合，间接评估冠脉微循环功能。这种“药理学探针”的方法为CMVD的诊断提供了实用工具。2. 急性心肌梗死急诊介入治疗中的保护作用在ST段抬高型心肌梗死（STEMI）患者急诊经皮冠状动脉介入治疗（PCI）中，术中应用腺苷可以有效预防慢血流/无复流现象的发生。其机制包括：· 扩张微血管，提高心肌组织水平的灌注· 通过多靶点机制减轻再灌注损伤· 抑制血小板活化和中性粒细胞黏附研究证实，STEMI患者急诊PCI时使用腺苷能更好地改善心肌灌注，减小心肌梗死面积，从而改善患者预后。4 儿科与感染性疾病中的应用拓展4.1 小儿疱疹性口腔炎的联合治疗小儿疱疹性口腔炎由单纯疱疹病毒Ⅰ型（HSV-1）引起，好发于6岁以下儿童。常规抗病毒治疗起效较慢，而单磷酸阿糖腺苷联合康复新液的方案显示出显著优势。一项纳入12项RCTs、共1094例患者的Meta分析表明，与单用单磷酸阿糖腺苷相比，联合康复新液能显著提高临床总有效率（RR=1.21），降低不良事件发生率（RR=0.26），并缩短疱疹消失时间、疼痛消失时间、退热时间等多项临床症状的恢复时间。康复新液通过促进口腔黏膜修复、抗炎和调节局部微环境，与单磷酸阿糖腺苷的抗病毒作用产生协同效应，是儿科疱疹性口腔炎的安全有效方案。4.2 小儿毛细支气管炎的辅助治疗毛细支气管炎是婴幼儿常见的下呼吸道感染，主要表现为喘息、呼吸困难。除常规的吸入糖皮质激素和支气管扩张剂外，加用单磷酸阿糖腺苷可进一步提升疗效。一项纳入122例患儿的随机对照试验显示，在布地奈德和复方异丙托溴铵基础上加用单磷酸阿糖腺苷，可将治疗7天后的总有效率从80.33%提高至93.44%，同时显著缩短喘息、湿啰音、咳嗽消失时间及住院时间。研究还发现，联合治疗能更有效地降低血清淀粉蛋白A（SAA）、白三烯E4（LTE4）和单核细胞趋化蛋白-1（MCP-1）等炎症标志物水平，改善肺功能指标，且不增加不良反应风险。5 肿瘤免疫治疗的新兴领域腺苷信号通路在肿瘤免疫微环境（TME）中扮演着关键免疫抑制角色，使其成为肿瘤免疫治疗的新兴靶点。5.1 腺苷在肿瘤免疫微环境中的作用在缺氧、炎症的肿瘤微环境中，ATP/ADP被CD39和CD73 ectonucleotidases依次水解，产生高浓度的腺苷。腺苷通过激活肿瘤细胞和免疫细胞（如调节性T细胞、髓源性抑制细胞）上的A2A和A2B受体，抑制效应T细胞和自然杀伤细胞的功能，促进血管生成，从而帮助肿瘤实现免疫逃逸。5.2 靶向腺苷信号通路的抗肿瘤策略目前针对腺苷信号通路的抗肿瘤策略主要包括：1. CD73抑制剂（如Quemliclustat）：阻断腺苷生成的上游关键酶。2. A2A/A2B受体双重拮抗剂（如Etrumadenant）：阻断腺苷的免疫抑制信号。3. 联合免疫检查点抑制剂：与PD-1/PD-L1抗体协同，逆转肿瘤免疫抑制。一项正在进行的II期临床试验（SBRT-AMICO）正在评估Etrumadenant、Quemliclustat联合PD-1抑制剂Zimberelimab及立体定向放疗（SBRT）对激素敏感性寡转移前列腺癌男性的疗效。该研究假设联合方案能改善局部控制、无进展生存期和无激素治疗生存期，同时减轻肿瘤微环境的免疫抑制状态。6 临床用药策略与规范建议6.1 精准化药物选择临床医生应根据治疗目标，精准选择不同类型的腺苷相关药物：· 心律失常紧急处理：选择腺苷注射液快速静脉注射，特别适用于窄QRS波心动过速的鉴别与终止。· 冠心病诊断与评估：根据医疗条件选择传统腺苷或瑞加诺生进行药物负荷试验，后者耐受性更佳。· 抗病毒感染：选择单磷酸阿糖腺苷，尤其适用于儿童疱疹病毒感染。· 营养神经与造血：选择腺苷钴胺，用于巨幼红细胞性贫血和周围神经病变。6.2 用法用量优化腺苷注射液用于PSVT：严格遵循“快速弹丸式注射”原则，初始剂量3mg，无效时依次递增至6mg、12mg，每次给药间隔1-2分钟。给药后必须用10-20ml生理盐水快速冲洗，确保药物完全进入循环。腺苷用于负荷试验：按140μg/kg/min的速度静脉输注，持续6分钟，总剂量0.84mg/kg。新型选择性激动剂瑞加诺生则采用固定剂量（0.4mg）单次静脉注射，操作更为简便。6.3 联合用药策略· 心血管领域：在STEMI急诊PCI中，腺苷可与尼可地尔、钙通道阻滞剂等联合应用，多途径保护微循环。· 儿科感染：单磷酸阿糖腺苷联合康复新液治疗疱疹性口腔炎，抗病毒与黏膜修复协同；联合吸入糖皮质激素和支气管扩张剂治疗毛细支气管炎，抗病毒与抗炎平喘协同。· 肿瘤免疫：CD73抑制剂、A2A/A2B受体拮抗剂与PD-1抑制剂及放疗联合，多靶点逆转免疫抑制。6.4 不良反应监测与禁忌管理腺苷注射液常见的不良反应包括面部潮红、呼吸困难、胸部紧压感、头晕等，但通常持续时间短暂（常短于1分钟）且患者耐受良好。严重但罕见的不良反应包括严重心动过缓、心脏停搏和支气管痉挛。绝对禁忌症包括：· II度或III度房室传导阻滞（已安装起搏器者除外）· 病态窦房结综合征（已安装起搏器者除外）· 已知或估计有支气管狭窄或支气管痉挛性肺疾病（如哮喘）· 对腺苷过敏者重要药物相互作用：· 双嘧达莫（潘生丁）：可抑制腺苷摄取，增强其作用4倍，合用时应将腺苷剂量减少至0.5-1.0mg。· 甲基黄嘌呤类药物：如茶碱、咖啡因，作为腺苷受体拮抗剂可能减弱腺苷作用。· 卡马西平：可能加重心脏传导阻滞。7 结论与展望腺苷及其衍生物作为连接基础生理与临床治疗的重要桥梁分子，已在心血管疾病、病毒感染、血液系统疾病等领域确立了明确的治疗地位。2024年《腺苷注射液在心血管疾病诊疗中的临床应用中国专家共识》的发布，标志着我国腺苷临床应用进入了规范化、精准化的新阶段。未来，腺苷相关药物的研发与应用将呈现以下趋势：心血管领域精细化：新型选择性A2A受体激动剂（如瑞加诺生）将逐步替代传统腺苷在负荷试验中的应用，其更好的安全性和便捷性有望提高冠脉微血管疾病的诊断率。同时，腺苷在心肌保护方面的多靶点机制将被进一步挖掘，可能催生新的心脏保护策略。肿瘤免疫治疗突破：针对腺苷-CD73-A2AR免疫抑制轴的药物研发是肿瘤免疫治疗的前沿热点。CD73抑制剂、A2A/A2B受体拮抗剂与现有免疫检查点抑制剂、放疗、化疗的联合方案，有望克服肿瘤免疫治疗耐药，扩大受益人群。个体化用药发展：基于药物基因组学的研究将帮助识别腺苷治疗反应的预测标志物，实现真正意义上的个体化给药。同时，新型给药系统和制剂技术的应用可能延长腺苷作用时间，拓展其治疗窗。在临床实践中，医生应充分理解各类腺苷药物的作用机制与特点，严格掌握适应症与禁忌症，遵循共识推荐的用药方案，同时关注新兴的研究证据，不断优化治疗策略，最终使患者从这一古老而新颖的药物家族中获得最大获益。---

寡核苷酸免疫疗法

2025-10-19

·investors.arcusbio.com

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

TOKYO & HAYWARD, Calif.--(BUSINESS WIRE)-- Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc. (NYSE:RCUS, “Arcus”) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International Nonproprietary Name; development code: AB521), an investigational small molecule HIF (Hypoxia Inducible Factor)-2α inhibitor, in Japan and certain other territories in Asia (excluding mainland China). This option exercise is based on a 2017 option and license agreement between Taiho and Arcus. This is the fifth option exercise by Taiho to an Arcus program. In exchange for the exclusive license to casdatifan, Taiho will make an option exercise payment, as well as additional payments upon achievement of clinical, regulatory and commercialization milestones, and, if any products from the program are approved, will pay royalties on net sales of such products. Casdatifan is an investigational small molecule compound developed by Arcus. Arcus is currently conducting an ongoing global, registrational Phase 3 study, PEAK-1,* comparing the combination therapy of casdatifan and a VEGFR-targeted tyrosine kinase inhibitor (TKI) to monotherapy using a VEGFR-targeted TKI alone in patients with clear cell renal cell carcinoma (ccRCC). Japan is also expected to participate in the study starting in the first half of 2026. *PEAK-1: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma Through this collaboration, Taiho and Arcus are committed to delivering casdatifan as a potentially innovative new medicine to patients and healthcare professionals as swiftly as possible. About Casdatifan (AB521) Casdatifan is a small-molecule inhibitor of HIF-2α, a master switch that turns on hundreds of genes in response to low oxygen levels; when oxygen levels return to normal, HIF-2α is turned off. In a majority of people with the most common form of kidney cancer (clear cell renal cell carcinoma), this shut-off mechanism is deficient and HIF-2α remains activated even in the presence of oxygen, causing normal kidney cells to become cancerous. Casdatifan is designed to provide deeper and more durable inhibition of the HIF-2α pathway. About clear cell renal cell carcinoma (ccRCC) Kidney cancer is a disease with a rising worldwide incidence estimated at 400,000 new cases annually, and a worldwide mortality rate approaching 175,000 deaths per year. Current projections suggest incidence continuing to increase over the next decade, emphasizing the urgency of addressing this significant global health trend. ccRCC is the most common type of kidney cancer in adults, making up 75-80% of all cases.1 About the Taiho and Arcus Agreement Based on the option and license agreement that Taiho and Arcus entered into in 2017, Taiho has obtained exclusive development and commercialization rights to a total of five Arcus programs in Japan and certain other territories in Asia (excluding mainland China): (1) casdatifan, HIF-2α inhibitor announced today; (2) etrumadenant, a dual A2a/b adenosine receptor antagonist program in 2018; (3) zimberelimab, the anti-PD-1 program in 2019; (4) domvanalimab, the anti-TIGIT program in 2021, and (5) quemliclustat, CD73 inhibitor program in 2024. About Taiho Pharmaceutical Co., Ltd. (Japan) Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the fields of oncology and immune-related diseases. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology, in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people’s efforts to lead fulfilling and rewarding lives. For more information about Taiho Pharmaceutical, please visit https://www.taiho.co.jp/en. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, an HIF-2α inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com. Arcus Forward-Looking Statements This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein, including, but not limited to, Arcus’s development plans for casdatifan, including the conduct of PEAK-1 in Japan; ability to deliver casdatifan as an innovative new medicine; and realization of any potential benefits from this transaction such as the receipt of future milestones and royalties, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause our actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: difficulties or delays in conducting or completing clinical trials due to difficulties or delays in the regulatory process, enrolling subjects or supplying investigational or standard of care products for such clinical trials, all of which may be exacerbated by unfavorable global economic, political and trade conditions; the unexpected emergence of adverse events or other undesirable side effects with casdatifan; changes in the competitive landscape; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus are described more fully in the “Risk Factors” section of Arcus’s most recent periodic report filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release. The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners. 1) Padala S. et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020 May 14;11(3):79–87. doi: 10.14740/wjon1279 Taiho Pharmaceutical Co., Ltd. Inquiries: Yuji Kawahara Strategic Communications +81-3-3293-2878 yuji-kawahara@taiho.co.jp Investor Inquiries: Pia Eaves VP of Investor Relations & Strategy (617) 459-2006 peaves@arcusbio.com Media Inquiries: Holli Kolkey VP of Corporate Affairs (650) 922-1269 hkolkey@arcusbio.com Maryam Bassiri AD, Corporate Communications (510) 406-8520 mbassiri@arcusbio.com

引进/卖出临床3期

100 项与 Etrumadenant 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期胰腺导管腺癌	临床2期	美国	Arcus Biosciences, Inc.	2024-05-10
去势敏感前列腺癌	临床2期	美国	Arcus Biosciences, Inc.	2023-07-01
寡转移性前列腺癌	临床2期	美国	Arcus Biosciences, Inc.	2023-07-01
晚期非小细胞肺癌	临床2期	美国	Gilead Sciences, Inc.	2023-03-16
晚期非小细胞肺癌	临床2期	巴西	Gilead Sciences, Inc.	2023-03-16
晚期非小细胞肺癌	临床2期	中国香港	Gilead Sciences, Inc.	2023-03-16
晚期非小细胞肺癌	临床2期	以色列	Gilead Sciences, Inc.	2023-03-16
晚期非小细胞肺癌	临床2期	韩国	Gilead Sciences, Inc.	2023-03-16
晚期非小细胞肺癌	临床2期	中国台湾	Gilead Sciences, Inc.	2023-03-16
晚期非小细胞肺癌	临床2期	土耳其	Gilead Sciences, Inc.	2023-03-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04791839 (SITC2025)	临床2期	非小细胞肺癌	30	Zimberelimab 360mg IV q3 weeks, Domvanalimab 15mg/kg IV q3 weeks and Etrumadenant 150mg PO daily	鹹簾獵網夢範淵壓範餘(選鏇艱網窪鑰選醖選糧) = 憲醖顧窪觸製憲築衊範繭艱鹽獵築遞淵憲齋網 (鑰艱壓顧夢簾範壓遞廠 ) 更多	不佳	2025-11-05
				Zimberelimab 360mg IV q3 weeks, Domvanalimab 15mg/kg IV q3 weeks and Etrumadenant 150mg PO daily (PD-L1 1-49%)	選憲簾淵遞艱構顧廠壓(夢選築蓋膚遞鬱鹹遞憲) = 淵網齋顧構遞製衊觸觸繭膚繭艱繭積積壓積鬱 (淵鹹觸醖範襯廠選範艱 ) 更多
NCT04660812 (ARC-9, SITC2024)	临床1/2期	结直肠癌三线 CD73-positive	92	Etrumadenant (etruma; AB928) + Zimberelimab (Z) + FOLFOX + Bevacizumab (bev) (EZFB regimen)	艱壓鹹襯憲顧範鬱選鬱(製窪淵壓鏇壓網壓廠繭): HR = 0.2 更多	积极	2024-11-05
				Regorafenib (rego)
NCT04660812 (ARC-9, ASCO2024) 人工标引	临床1/2期	转移性结直肠癌	112	Etrumadenant+zimberelimab+mFOLFOX-6±bevacizumab	糧膚鏇製廠鹹襯餘繭壓(淵鑰齋鏇鏇餘衊網蓋獵) = 選膚膚顧膚築衊網壓簾衊鏇襯憲醖製鹽網鹹廠 (網範醖觸鏇糧製膚艱繭, 5.5 ~ 7.5) 更多	积极	2024-05-24
				regorafenib	糧膚鏇製廠鹹襯餘繭壓(淵鑰齋鏇鏇餘衊網蓋獵) = 積鏇鬱構繭顧醖獵糧鬱衊鏇襯憲醖製鹽網鹹廠 (網範醖觸鏇糧製膚艱繭, 1.8 ~ 3.0) 更多
NCT04262856 (ARC-7, Corporate Publications) 人工标引	临床2期	非小细胞肺癌一线	150	zimberelimab	鹹淵窪鹹鑰製鬱繭鑰醖(構鹽衊淵蓋選餘築鬱醖) = 鬱廠襯憲壓網襯鬱選網夢網簾積膚簾顧鬱鏇廠 (廠衊繭願顧憲襯遞廠鏇, 17.9 ~ 44.6) 更多	积极	2023-06-03
				domvanalimab + zimberelimab	鹹淵窪鹹鑰製鬱繭鑰醖(構鹽衊淵蓋選餘築鬱醖) = 襯願艱醖窪醖襯範觸憲夢網簾積膚簾顧鬱鏇廠 (廠衊繭願顧憲襯遞廠鏇, 26.4 ~ 54.8) 更多
NCT04262856 (ARC-7, ASCO2022) 人工标引	临床2期	转移性非小细胞肺癌一线 PD-L1 High Expression	149	zimberelimab	憲簾壓窪鏇壓簾窪窪顧(衊齋範窪築願網齋夢衊) = 築遞糧鑰繭鏇襯衊鏇淵蓋糧鹹範積衊壓顧鬱廠 (鬱糧範餘構築選觸簾衊, 15.0 ~ 42.8) 更多	积极	2022-12-20
				domvanalimab+zimberelimab	憲簾壓窪鏇壓簾窪窪顧(衊齋範窪築願網齋夢衊) = 淵範壓襯構願鹹糧鏇積蓋糧鹹範積衊壓顧鬱廠 (鬱糧範餘構築選觸簾衊, 26.3 ~ 56.8) 更多
NCT04381832 (ARC-6, ASCO 12021 \| ASCO 22021) 人工标引	临床1/2期	去势抵抗性前列腺癌	-	zimberelimab+docetaxel+etrumadenant	窪淵壓鏇鹹觸淵窪憲醖(蓋齋艱鏇鹹蓋鹹餘餘鑰) = 構顧築鹹膚積憲構窪窪積製艱簾襯窪簾餘構鏇 (願願繭簾範製製齋獵窪 ) 更多	积极	2021-05-28
NCT03720678 (ARC-3, AACR 12021 \| AACR 22021) 人工标引	临床1期	转移性结直肠癌	44	mFOLFOX-6+AB928	鹽艱廠繭鹽觸網齋鹹鬱(願壓淵夢壓憲製選憲齋) = 簾製廠窪獵艱簾鬱鏇艱選積艱遞築網選繭觸選 (窪憲築淵選選構蓋蓋廠 ) 更多	积极	2021-04-10
				mFOLFOX-6+AB928 (3L+ pts)	鬱構願鬱襯範壓觸蓋遞(蓋憲膚糧鑰顧糧壓餘簾) = 遞蓋廠艱憲鏇獵糧選繭衊鹽夢鏇壓鏇積窪願鏇 (鬱鏇遞糧遞鏇選齋網範 ) 更多
NCT03719326 (ARC-2, AACR2021) 人工标引	临床1期	卵巢癌 \| 转移性三阴性乳腺癌	29	AB928 150 mg + pegylated liposomal doxorubicin (Doublet)	製選衊艱鹽廠夢簾襯製(襯構獵選鹽夢觸膚鑰蓋) = Four pts reported 6 Gr ≥3 SAEs 糧選糧鏇鹽獵鏇範糧鏇 (範衊淵鹽鏇窪糧鹽淵齋 ) 更多	积极	2021-02-15
				IPI-549 40 mg + AB928 150 mg + pegylated liposomal doxorubicin (Triplet)
NCT03846310 (ARC-4, ESMO2020) 人工标引	临床1期	转移性非小细胞肺癌	11	AB928+carboplatin+pemetrexed+zimberelimab	蓋獵窪糧積襯鹹餘衊窪(顧鏇繭窪範壓鑰齋廠範) = Two pts experienced SAEs (Gr4 thrombocytopenia [n=1], pyrexia, vomiting, rash [n=1]) that were related to AB928. 願夢醖觸鑰網觸鹹網獵 (範範衊憲繭鹹鹹壓觸獵 ) 更多	积极	2020-09-17
NCT03720678 (ARC-3, AACR2020)	临床1期	转移性结直肠癌	40	AB928 150 mg + mFOLFOX-6	艱簾範範廠願蓋繭窪鹹(構構鑰壓繭壓壓範鬱鬱) = AB928-related Grade 3 AEs reported by 3 pts were diarrhea, AST increase, and neutropenia; there were no Grade 4-5 AB928-related AEs 膚醖窪鹹壓鹹構齋觸願 (構鹹築繭範鑰壓獵夢衊 ) 更多	-	2020-08-15